Litak® (Cladribine) - 2 mg/ml

Name Litak®
Description Cladribine is an antineoplastic agent of the following pharmacotherapeutic group: antineoplastic agents, antimetabolites, purine analogues (ATC-Code: L01BB04). The selective toxicity cladribine towards certain normal and malignant lymphocyte and monocyte populations is based on the relative activities of deoxycytidine kinase, deoxynucleotidase and adenosine deaminase. It is postulated that cells with high deoxycytidine kinase and low deoxynucleotidase activities will be selectively killed by cladribine as toxic deoxynucleotides accumulate intracellularly. Cells containing high concentrations of deoxynucleotides are unable to properly repair single-strand DNA breaks.
Active Ingredient Cladribine
Indication Litak® is a solution for injection that contains the active substance cladribine to treat rare forms of leukemia or lymphoma.
Strengths 2 mg/ml
Business Partner Lipomed
Origin Switzerland